Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
163.2 INR | +6.10% | +6.60% | 0.00% |
Income Statement Evolution (Annual data)
Fiscal Period: März | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales 1 | 507.9 | 624.7 | 823.8 | 955.8 |
EBITDA 1 | 121.6 | 141.6 | 191.3 | 221.1 |
EBIT 1 | 112 | 131.8 | 180.8 | 207.7 |
Operating Margin | 22.05% | 21.09% | 21.95% | 21.73% |
Earnings before Tax (EBT) 1 | 117.4 | 135 | 183.4 | 223.3 |
Net income 1 | 85.94 | 99.56 | 136.1 | 166.2 |
Net margin | 16.92% | 15.94% | 16.52% | 17.39% |
EPS 2 | 2.122 | 2.550 | 3.486 | 4.310 |
Free Cash Flow | - | 77.05 | 23.3 | 79.45 |
FCF margin | - | 12.33% | 2.83% | 8.31% |
FCF Conversion (EBITDA) | - | 54.4% | 12.18% | 35.94% |
FCF Conversion (Net income) | - | 77.39% | 17.12% | 47.81% |
Dividend per Share | - | - | - | - |
Announcement Date | 21-07-14 | 21-07-14 | 22-08-01 | 23-11-24 |
Balance Sheet Analysis
Fiscal Period: März | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | 24.5 | 46.4 | 66.4 | 56.5 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | 77 | 23.3 | 79.5 |
ROE (net income / shareholders' equity) | - | 39.2% | 40.2% | 39.1% |
ROA (Net income/ Total Assets) | - | 22.8% | 23.8% | 23.4% |
Assets 1 | - | 436.3 | 572.3 | 709.2 |
Book Value Per Share 2 | 5.760 | 7.020 | 10.40 | 12.00 |
Cash Flow per Share 2 | 0.2000 | 0.2700 | 0.7200 | 0.9600 |
Capex 1 | 15.9 | 16.5 | 38 | 84.2 |
Capex / Sales | 3.13% | 2.64% | 4.61% | 8.8% |
Announcement Date | 21-07-14 | 21-07-14 | 22-08-01 | 23-11-24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 72.54M | |
+20.09% | 68.02B | |
-5.30% | 46.34B | |
+22.19% | 43.77B | |
+36.70% | 28.93B | |
+11.89% | 19.86B | |
+14.26% | 17.23B | |
-25.77% | 14.95B | |
-14.93% | 14.44B | |
-31.27% | 11.82B |
- Stock Market
- Equities
- KRONOX Stock
- Financials Kronox Lab Sciences Limited